^
1m
Mutational Landscape and Clinicopathologic Features of Plasmablastic Lymphoma (USCAP 2024)
In conclusion, our findings shed light on the unique molecular complexity of PBL, unveiling its mutational landscape and potential therapeutic targets. Due to the rarity of PBL, further research with a more extensive sample size is essential to completely elucidate the mutational landscape of PBL.
Clinical
|
KRAS (KRAS proto-oncogene GTPase) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • NOTCH1 (Notch 1) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • TNFRSF8 (TNF Receptor Superfamily Member 8) • STAT3 (Signal Transducer And Activator Of Transcription 3) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • SDC1 (Syndecan 1) • TCF3 (Transcription Factor 3) • CCND3 (Cyclin D3) • CD79A (CD79a Molecule) • TNFRSF13B (TNF Receptor Superfamily Member 13B)
|
KRAS mutation • KRAS G12V • MYD88 mutation • KRAS G12 • KRAS G13 • PDGFRA mutation • STAT3 mutation
|
Archer® FusionPlex® Lymphoma
1year
CD56-positive diffuse large B-cell lymphoma: comprehensive analysis of clinical, pathological, and molecular characteristics with literature review. (PubMed, Radiol Oncol)
We report on one of the largest series of CD56+DLBCL with detailed clinicopathological data and for the first time described genetical findings in a limited number of patients. Our results show that CD56 expression is rare, but seems to be present in prognostic favourable subtypes of DLBCL not otherwise specified (NOS) as tested by immunohistochemical or genetic profiling.
Journal • Review
|
NCAM1 (Neural cell adhesion molecule 1)
|
KIT expression • NCAM1 expression
|
Archer® FusionPlex® Lymphoma
over1year
Integrated DNA Technologies Acquires ArcherDX Next Generation Sequencing Research Assays from Invitae Corporation (Integrated DNA Technologies Press Release)
"Integrated DNA Technologies, Inc....announced it closed on the purchase of Next Generation Sequencing (NGS) research assays from Invitae Corporation (NYSE: NVTA) under the trademarked name Archer. The integration of IDT’s portfolio with the acquired NGS research assays—which have been foundational in researching novel cancer fusions—will empower labs with an all-in-one solution to uncover biomarkers and advance cancer discoveries. The transaction enables IDT to expand its existing operations, build upon the legacy Archer portfolio, and welcome more than 100 new associates globally....Transaction Details-IDT purchased Archer NGS research assays—which reported high double-digit growth since 2019—from Invitae for cash consideration of approximately $48 million, subject to certain adjustments. The transaction is structured as an asset deal and includes a license to intellectual property related to the AMP technology."
M&A
|
Archer® FusionPlex® Comprehensive Thyroid & Lung (CTL) Kit • Archer® FusionPlex® Acute Lymphoblastic Leukemia (ALL) • Archer® FusionPlex® Lung Kit • Archer® FusionPlex® Lymphoma • Archer® FusionPlex® Myeloid Kit • Archer® FusionPlex® Oncology Research Kit • Archer® FusionPlex® Sarcoma kit • Archer® VariantPlex® Comprehensive Thyroid and Lung (CTL) kit • Archer® VariantPlex® Myeloid panel • Archer® VariantPlex® Solid Tumor Kit • FusionPlex® Dx • FusionPlex® Pan Solid Tumor v2 panel • FusionPlex™ Heme v2 panel • FusionPlex™ Pan-Heme panel • LiquidPlex™
over1year
Orthotopic Xenografts Models in Relapse/Refractory Lymphomas: A Preclinical Model for Therapeutic, Mechanistic and Functional Studies (ASH 2022)
To our knowledge, these are one of the first orthotopic PDX lymphoma models generated, that can allow us to expand patients' refractory tumors in order to extensively study molecular features of them and target effective drug profiles.
Preclinical • IO biomarker
|
Archer® FusionPlex® Lymphoma
over2years
[VIRTUAL] Clinical Validation of Multiplexed Fusion Panel by NextGeneration Sequencing in Lymphoproliferative Diseases (AMP 2021)
We have validated an AFPLP with faster turnaround time obtained due to changes done in the library normalization step. By using our preestablish metrics, the AFPLP demonstrated high sensitivity, accuracy, reproducibility, and precision for the detection of fusion isoforms in lymphoproliferative diseases from FFPE samples. These metrics allowed us to assess fusion genes with optimal nucleotide-level resolution of fusion breakpoints, thereby minimizing false positive/negative rates.
Clinical • Next-generation sequencing
|
ALK (Anaplastic lymphoma kinase) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • EML4 (EMAP Like 4) • NPM1 (Nucleophosmin 1) • ETV6 (ETS Variant Transcription Factor 6)
|
NTRK3 fusion • ALK fusion • ETV6-NTRK3 fusion
|
Archer® FusionPlex® Lymphoma